Failure of Helicobacter pylori treatment after regimes containing clarithromycin: New practical therapeutic options

Helicobacter

Volumn 13, Issue 6, 2008, Pages 572-576

  Sanches, Bruno ^a   Coelho, Luiz ^a,b   Moretzsohn, Luciana ^a   Vieira Jr , Gerival ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Clarithromycin failure; Helicobacter pylori; Retreatment

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; DOXYCYCLINE; FURAZOLIDONE; LEVOFLOXACIN; OMEPRAZOLE; RABEPRAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BITTER TASTE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UREA BREATH TEST; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-ULCER AGENTS; BREATH TESTS; CLARITHROMYCIN; DOXYCYCLINE; FEMALE; FURAZOLIDONE; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; UREA;

HELICOBACTER PYLORI;

EID: 55949093740     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00649.x     Document Type: Article

References (20)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007 56 : 772 81.
2. Chey WD, Wong BCY, American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1 18.
3. Vakil N, Lanza F, Schwatrz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004 20 : 99 107.
4. Bochenek WL, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003 8 : 626 42.
5. Gisbert JP, Pajares JM. Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 57.
6. Coelho LGV, Zaterka, S. Federação Brasileira de Gastroenterologia e Núcleo Brasileiro para o Estudo de Helicobacter. Second Brazilian Consensus Conference on Helicobacter pylori Infection. Arq Gastroenterol 2005 42 : 128 32.
7. Sotoudehmanesh R, Malekzadeh R, Vahedi H, et al. Second-line H. pylori eradication with a regimen containing furazolidone in patients who have failed a metronidazole-based regimen. Digestion 2001 64 : 222 5.
8. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 84.
9. Graham DY, Belson G, Abudayyeh S, et al. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis 2004 36 : 384 7.
10. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
11. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 96.
12. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005 21 : 783 7.
13. Coelho LG, Reber M, Passos MC, et al. Application of isotope-selective non-dispersive infrared spectrometry for the evaluation of the 13C-urea breath test: comparison with three concordant methods. Braz J Med Bio Res 1999 32 : 1493 7.
14. De Boer WA, Thys JC, Borody TJ, et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996 8 : 641 3.
15. Gisbert JP, Gisbert JL, Marcos S, et al. Levofloxacin versus ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007 12 : 68 73.
16. Lambert JR, Arena G. Mucosal antibiotic levels. In : Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori. Basic Mechanisms to Clinical Cure. Dordrecht, The Netherlands : Kluwer Academic Publishers, 1994 538 49.
17. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007 26 : 495 500.
18. Zaterka S, Ribeiro L, Silva E, et al. A multicenter study to compare the efficacy and safety of 3-7-day rabeprazole (RAB)-based triple therapy regimens for Helicobacter pylori eradication. Gastroenterology 2003 124 : A360.
19. Coelho LG, Martins GM, Passos MC, et al. Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. Aliment Pharmacol Ther 2003 17 : 131 6.
20. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 1339 43.